2018 INTERIM REPORT

TABLE OF CONTENTS

This Interim Report contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond MDxHealth's control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this Interim Report to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation.

I. INTERIM MANAGEMENT REPORT

Highlights

Key non-audited financials, as of June 30, 2018

Amounts as at and for the six months ended

USD thousands	June 30, 2018	June 30, 2017
Total revenues	17,200	24,260
Total operating expenses	25,478	18,709
EBITDA Profit/(Loss)	-13,472	1,433
Operating profit (EBIT)	-14,952	552
Net Profit/(Loss)	-15,113	538
Earnings/(loss) per share, basic ($)	-0.27	0.01
Number of outstanding shares	59,939,289	49,949,408
Cash and cash equivalents	40,933	30,509

Total revenue for the first half was $17.2 million compared to normalized total revenue of $12.2 million during the same period in 2017. Including the one-time $12.1 million revenue from the sale of patents to Exact Sciences, H1 2017 total revenue amounted to $24.3 million. Product and services revenue of $16.6 million compared to $12.0 million in the same period last year. Revenue from ConfirmMDx and SelectMDx amounted to $15.3 million and increased 29% from $11.9 million a year earlier. Revenue from ConfirmMDx represented 92% of product revenue. Product revenue from SelectMDx grew 46% from $0.8 million in 2017 to $1.1 million in 2018.

Revenue recognized on the sales of ConfirmMDx and SelectMDx represented just over 51% of total gross billings, a slight increase from 50% in the first half of 2017, with a marginal improvement in the revenue recognition rate for ConfirmMDx being offset by the lower rate applicable to the fast-growing test volumes of SelectMDx.

Operating expenses in the first half year were $25.5 million, up $6.8 million over the same period last year, largely related to the expansion of the Company's commercial operations, including the building out of a global US sales force, and increased amortization charges on internally developed intangible assets.

Operating loss (EBIT) and net loss for the first half year were $15 million and $15.1 million, an increase of respectively $15.5 million and $15.7 million over the same period in 2017. Excluding royalties, the gross profit on products and services improved by $3 million to $10 million, and was offset by the increased operating costs reflecting primarily further investment in commercialization.

Cash and cash equivalents as of June 30, 2018 were $40.9 million. In March 2018, the Company raised $44 million (€36 million) in gross proceeds by means of a private placement of 9,989,881 new shares at an issue price of EUR 3.60 per share through an accelerated book building. Cash collections from ConfirmMDx and SelectMDx amounted to $14.7 million, an increase of 35% compared to last year. The operational cash burn of $15 million was further impacted by $1.3 million investments in tangible and intangible assets.

Justification to continue using the accounting rules on the basis of going concern

Despite cumulated losses, the Board has decided to continue to apply the accounting rules on the basis of going concern. This decision is justified by (i) the success of the technology of the Company in various cancer applications and scientific publications, (ii) continued interest in the Company's technology, (iii) the continued industry growth in the field of molecular diagnostics and personalized medicine, and (iv) the fact that sufficient cash is available to support further development of the Company's products over the next 12 months period in function of the current business plan. Considering the situation, the Board

of Directors believes that there is enough cash to sustain the current projects of the Company at least for the coming twelve months.

Principal risks related to the business activities

The principal risks related to the MDxHealth's business activities have been outlined in the 2017 Annual Report, which is available on the internet at www.mdxhealth.com/investors/financials.htm.

Declaration of responsible persons

The Board of Directors of MDxHealth SA, represented by all its members, declares that, as far as it is aware, the financial statements in this Interim Report, made up according to the applicable standards for financial statements, give a true and fair view of the equity, financial position and the results of the company and its consolidated companies. The Board of Directors of MDxHealth SA, represented by all its members, further declares that this Interim Report gives a true and fair view on the information that has to be contained herein. The condensed consolidated interim financial statements have been prepared in accordance with International Accounting Standard (IAS) 34 (Interim Financial Reporting) as adopted by the European Union.

II. INTERIM CONDENSED UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
MDxHealth SA
For the six months ended June 30, 2018

1. CONDENSED UNAUDITED CONSOLIDATED STATEMENT OF PROFIT AND LOSS AND OTHER COMPREHENSIVE INCOME

In thousands of USD

Condensed unaudited consolidated statement of profit and loss

	Note	Jan-June 2018	Jan-June 2017
Product and service income	**4**	16,638	12,004
Patent income	**4**	500	7,000
Royalties	**4**	62	5,256
Revenues		**17,200**	**24,260**
Cost of goods and services sold		6,674	4,999
Gross Profit		**10,526**	**19,261**
Research and development expenses	5	1,898	832
Selling, general and administrative expenses	5	23,682	17,903
Other operating income		116	26
Other operating expenses		26	0
Operating profit/(loss) (EBIT)		**-14,952**	**552**
Financial income		12	16
Financial expenses		157	86
Profit/(loss) before income taxes		**-15,097**	**482**
Income taxes		16	(56)
Profit/(loss) for the period		**-15,113**	**538**
Earning/(loss) per share (EPS)		-0.27	0.01
Basic, in USD		-0.27	0.01
Diluted, in USD			

Condensed unaudited consolidated statement of other comprehensive income

Profit/(loss) for the period	**-15,113**	**538**
Other comprehensive income		
Items that will be reclassified to profit or loss:		
Exchange differences arising on translation of foreign operations	-1,754	1,299
Total comprehensive income for the period (net of tax)	**-16,867**	**1,837**

2. CONDENSED UNAUDITED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

In thousands of USD

	Note	as at June 30, 2018	as at Dec 31, 2017
ASSETS			
Goodwill		1,145	1,145
Other intangible assets	**6**	15,346	15,492
Property, plant and equipment		2,430	2,568
Non-current assets		**18,921**	**19,205**
Inventories		1,411	1,919
Trade receivables	**7**	21,069	19,825
Prepaid expenses and other current assets		871	745
Cash and cash equivalents	**7**	40,933	16,827
Current assets		**64,284**	**39,316**
Total assets		**83,205**	**58,521**
EQUITY			
Share capital		53,877	45,946
Issuance premium		135,731	101,239
Accumulated loss		-111,088	-98,800
Result for the period		-15,113	-12,288
Share-based compensation		6,756	6,212
Translation reserves		-517	1,237
Total shareholders' equity		**69,646**	**43,546**
LIABILITIES			
Loans and borrowings		390	523
Deferred tax liabilities		632	616
Other non-current liabilities		0	60
Long term liabilities	**7**	1,101	661
Non-current liabilities		**2,123**	**1,860**
Loans and borrowings		300	361
Trade payables	**7**	6,963	8,055
Other current liabilities	**7**	3,764	3,816
Short-term liabilities	**7/9**	409	883
Current liabilities		**11,436**	**13,115**
Total liabilities		**13,559**	**14,975**
Total shareholders' equity and liabilities		**83,205**	**58,521**

MDxHealth

3. CONDENSED UNAUDITED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY

Attributable to owners of MDxHealth SA

In thousands of USD	Number of shares	Share capital	Share Premium	Acumulated loss	Share-based compensation	Translation reserve	Total Equity
Balance at January 1, 2017	**49,845,595**	**45,853**	**101,105**	**-98,800**	**5,269**	**-686**	**52,741**
Profit for the period				538			**538**
Other comprehensive income						1,299	**1,299**
Total comprehensive income for the period				**538**		**1,299**	**1,837**
Transactions with owners in their capacity as owners:							
Issuance of shares	103,813	93	134				**227**
Share-based compensation					365		**365**
Balance at June 30, 2017	**49,949,408**	**45,946**	**101,239**	**-98,262**	**5,634**	**613**	**55,170**

In thousands of USD	Number of shares	Share capital	Share Premium	Accumulated loss	Share-based compensation	Translation reserve	Total Equity
Balance at January 1, 2018	**49,949,408**	**45,946**	**101,239**	**-111,088**	**6,212**	**1,237**	**43,546**
Loss for the period				-15,113			**-15,113**
Other comprehensive income						-1,754	**-1,754**
Total comprehensive income for the period				**-15,113**		**-1,754**	**-16,867**
Transactions with owners in their capacity as owners:							
Issuance of shares, net of transaction costs (note 11)	9,898,881	7,931	34,492				**42,423**
Share-based compensation					544		**544**
Balance at June 30, 2018	**59,939,289**	**53,877**	**135,731**	**-126,201**	**6,756**	**-517**	**69,646**

4. CONDENSED UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOWS

In thousands of USD

	Jan-June 2018	Jan-June 2017
CASH FLOWS FROM OPERATING ACTIVITIES		
Operating profit/(loss)	(14,952)	552
Depreciation, amortization and impairment	1,480	881
Share-based compensation	544	365
Interest paid	(13)	(10)
Decrease in inventories	508	91
(Increase)/decrease in accounts receivable	(1,370)	2,417
(Decrease) in accounts payable	(1,238)	(2,266)
Other non-cash transactions	(144)	(126)
Total adjustments	(233)	1,352
Net cash inflow/(outflow) from operating activities	**(15,185)**	**1,904**
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchase of property, plant and equipment	(423)	(451)
Purchase of intangible assets	(776)	(2,231)
Earn out related to business combination	0	(1,105)
Net cash (outflow) from investing activities	**(1,199)**	**(3,787)**
CASH FLOWS FROM FINANCING ACTIVITIES		
Proceeds from borrowings	0	296
Repayments of borrowings	(194)	(297)
Interest received	12	4
Proceeds from issuance of shares (net of transaction costs)	42,423	227
Net cash inflow/(outflow) from financing activities	**42,241**	**230**
Net increase/(decrease) in cash and cash equivalents	**25,857**	**(1,653)**
Cash and cash equivalents at beginning of the period	**16,827**	**30,871**
Effect of exchange rates	(1,751)	1,291
Cash and cash equivalents at end of the period	**40,933**	**30,509**

5. EXPLANATORY NOTES

Accounting policies

1. Basis of preparation

The condensed consolidated interim financial statements have been prepared in accordance with International Accounting Standard (IAS) 34 - Interim Financial Reporting, as adopted by the European Union.

These interim consolidated financial statements do not include all the information required for full annual financial statements and should be read in conjunction with the consolidated financial statements of the Company as at and for the year ended December 31, 2017. The reporting and functional currency of the Company is the U.S. Dollar.

The preparation of the condensed consolidated interim financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated interim financial statements and the reported amounts of revenue and expenses during the reporting period. If in the future such estimates and assumptions, which are based on management's best estimates and judgment, deviate from the actual circumstances, the original estimates and assumptions will be modified and the effects of the revisions will be reflected in the period in which the circumstances change.

Notwithstanding the losses sustained during the Company's existence, the Company has closed this reporting period with $40,933 thousand under Cash & cash equivalents. The company expects to continue to incur losses during the last 6 months of the financial year 2018. Based on the current cash availability, the board of directors however believes that the future research programs and the Company activities can be continued for more than one year. Consequently, the accounts have been prepared on a going concern basis.

2. Significant accounting policies

The Company applies the International Financial Reporting Standards (IFRS) as adopted by the European Union. The same accounting policies, presentation and methods of computation have been followed in these condensed financial statements as were applied in the preparation of the Group's financial statements for the year ended December 31, 2017, except for the impact of the adoption of the Standards and Interpretations described below.

New Standards, Interpretations and Amendments adopted by the Group

During the current financial year, the Group has adopted all the new and revised Standards and Interpretations issued by the International Accounting Standards Board (IASB) and the International Financial Reporting Interpretations Committee (IFRIC) of the IASB, that are relevant to its operations and effective for the accounting year starting on January 1, 2018. The Group has not applied any new IFRS requirements that are not yet effective as per June 30, 2018.

- IFRS 2 Share-based Payment — Amendments to clarify the classification and measurement of share-based payment transactions (June 2016)
- IFRS 9 Financial Instruments — Classification and Measurement (Original issue July 2014, and subsequent amendments)
- IFRS 15 Revenue from Contracts with Customers (Original issue May 2014 and subsequent amendments)
- IFRS 15 Revenue from Contracts with Customers – Clarifications (Original issue April 2016)
- IFRIC 22 Foreign Currency Transactions and Advance Consideration (December 2016)

The following new standards, interpretations and amendments, which have not been applied in these financial statements, will or may have an effect on the group's future financial statements:

IFRS 9, financial instruments was implemented under the exemption not to restate comparative information for prior periods. No adjustments to the carrying amounts of financial assets and liabilities resulting from the adaption of the standard were made in retained earnings or reserves at January 1, 2018.

IFRS 15, revenue from contracts with customers. This standard addresses the recognition of revenue, replacing IAS 18 which covers contracts for goods and services and IAS 11 which covers construction contracts. IFRS 15 sets out that revenue is recognized by reference to contracts and performance requirements and the stage of fulfilment of such performance obligations and to provide users of financial statements with more relevant disclosures. The standard is based on the principle that revenue is recognized when control of a good or service transfers to a customer so the notion of control replaces the existing notion of risks and rewards. It provides a single, principles based five step model to be applied to all contracts with customers as follows:

- Identify the contract(s) with a customer
- Identify the performance obligations in the contract
- Determine the transaction price
- Allocate the transaction price to the performance obligations in the contract
- Recognise revenue when (or as) the entity satisfies a performance obligation

Management has assessed the impact of the new standard and has not identified any areas of revenue recognition that have any material impact. In particular, a detailed analysis has been performed on product and service income. These services do not include amounts for which it is probable that a significant reversal will occur. The standard was adopted using the cumulative effect option.

As there is no impact resulting from the application of IFRS 15, the Company will adopt IFRS 15 using the cumulative effect option. No adjustments resulting from the adoption of the standard are expected to be made in retained earnings and reserves on initial application at 1 January 2018.

Standards and Interpretations issued but not yet effective in the current period

The Group elected not to early adopt the following new Standards, Interpretations and Amendments, which have been issued but not yet endorsed by the European Union as per June 30, 2018.

- Annual Improvements to IFRSs 2015-2017 Cycle (December 2017) *
- IFRS 9 Financial Instruments – Amendments regarding prepayment features with negative compensation (October 2017)
- IFRS 16 Leases (Original issue January 2016)
- IAS 19 Employee Benefits – Amendments relating to Plan Amendment, Curtailment or Settlement (February 2018) *
- IFRIC 23 Uncertainty over Income Tax Treatments (June 2017) *

** Not yet endorsed by the EU as of June 30, 2018*

None of the other new standards, interpretations and amendments, which are effective for periods beginning after July 1, 2018 and which have not been adopted early, are expected to have a material effect on the Group's future financial statements, except for the application of IFRS 16 Leases (mandatorily effective for periods beginning on or after January 1, 2019). The Company has completed an initial evaluation of the potential impact on its consolidated financial statements but has not yet completed its detailed assessment. It is therefore not yet possible to estimate the amount of right-of-use assets and lease liabilities that will have to be recognized on adoption of the new standard

and how this may affect the company's profit and losses and classification of cash flows going forward.

The preparation of the interim condensed financial statements in compliance with IAS 34 requires the use of certain critical accounting estimates. It also requires the Company's management to exercise judgment in applying the Company's accounting policies.

For information regarding our critical accounting policies and accounting estimates as well as certain recent accounting pronouncements, we refer to note 2.4 to the 2017 consolidated financial statements included in our Annual Report.

3. Revenues

Thousands of $ For the years ended June 30	2018	2017
Product and service income	16,638	12,004
Patent income	500	7,000
Royalties	62	5,256
Total	17,200	24,260

The commercial revenues other than direct sales for ConfirmMDx for Prostate Cancer were primarily generated from royalties and milestone fees, services provided to pharmaceutical companies, and sales of SelectMDx.

Revenue generated by our product and services for the period ended June 30, 20187, increased by 34% to $16,638 thousand, compared to $212,004 thousand a year earlier. Total revenue included the sale of the Company's patents directed towards colorectal cancer to Exact Sciences in 2017 and the sale of the Company's patents towards MGMT to LabCorp in 2018.

4. Operating expenses

Operating expenses in the first half year were $25.5 million, up $6.8 million over the same period last year, largely related to the expansion of the Company's commercial operations, including the building out of a global US sales force, and increased amortization charges on internally developed intangible assets.

5. Segment information

Information for the company's segment information has been determined by reference to the information used by the chief operating decision maker of the company [CODM] to review the performance of the company and in making decisions on allocation of resources, the nature of the activities and the management structure and accountabilities. The company's CEO has been identified as the chief operating decision maker in accordance with his designated responsibility for the allocation of resources to operating segments and assessing their performance through periodic reporting. The CODM periodically reviews the company's performance based on information at a company level. The company does not distinguish different business segments since most revenues are generated from clinical laboratory service testing, or the out-licensing of the company's patented DNA methylation platform and biomarkers. On an ancillary and opportunistic basis, the company may engage in contracting out its R&D and scientific expertise to commercial and non-commercial entities. The company is not organized nor does it operate along business lines and all functions supported all the company's commercial endeavours.

Total geographical external revenue of customers and geographical non-current assets is shown in the following graph.



In addition to the revenues related to the commercialization of our tests, revenues for 2017 included the proceeds from the sale of the license to Exact Sciences.

6. Capitalisation of internal developed projects

Generally, the Company considers that the regulatory and clinical risks inherent to the development of its products preclude it from capitalizing development costs. Development costs for products that will be sold can be capitalized as an intangible asset. It is dependent upon management's judgment that a technological and economic basis exists and that a project has reached a feasibility, clinical acceptance and subsequence commercialization milestone that supports the likelihood of revenue generation. Also the costs must be identifiable to meet the requirements for capitalization. Similar to the product development costs related to improving capacity, quality, and reagent costs, the study costs for clinical utility, health economic studies, decision impact studies, and comparative effectiveness are all mandatory requirements under the MolDx program to qualify for clinical use and reimbursement contracts with government and third party payor organizations. These studies are an integrated part of the of the product development. Without these studies the Company has no viable product and the product will be labeled for research or investigational use only.

During 2017, the Company capitalized internally generated development costs related to the enhancement of the ConfirmMDx for Prostate assay, but also for the development & improvement of SelectMDx and AssureMDx, and finally for the implementation of a new operating system, for a total of $3,682 thousand. At the end of 2017, the Company has capitalized under Developed Assets a total of $8,531 thousands and continued to capitalize under the same projects a total of $600 thousands in 2018.

7. Financial instruments and fair value

The carrying value and fair value of the financial instruments for 30 June 2018 and 31 December 2017 can be presented as follows:

In thousands of USD **For the periods ended**	**June 30, 2018**	**December 31, 2017**	**Hierarchy**
Financial assets at amortized cost			
Trade receivables	21,069	19,825	
Cash and cash equivalents	40,933	16,827	
Total financial assets	**62,002**	**36,652**	
Financial liabilities at fair value:			
Contingent consideration payable	1,510	1,544	Level 3

Subtotal financial liabilities at fair value	**1,510**	**1,544**
Financial liabilities at amortized cost:		
Loans and borrowings	690	884
Trade payables	6,963	8,055
Other liabilities	3,764	3,816
Subtotal financial liabilities at amortized cost	**11,417**	**12,755**
Total financial liabilities	**12,927**	**14,299**

The carrying value of the financial instruments has been determined on the basis of the following methods and assumptions :

- The carrying value of the cash and cash equivalents, the trade receivables, the trade payables and the other liabilities approximate their fair value due to their short term character;
- Loans and borrowings are evaluated based on their interest rates and maturity date. Their fair value approximates their carrying value.
- The fair value of contingent consideration payable is based on an estimated outcome of the conditional purchase price/contingent payments arising from contractual obligations. This is initially recognized as part of the purchase price and subsequently fair valued with changes recorded through profit and loss. The Company used a discount rate of 9.30%.

Fair value hierarchy
The Company uses the following hierarchy for determining and disclosing the fair value of financial instruments by valuation technique:

- Level 1 : quoted prices in active markets for identical assets and liabilities;
- Level 2 : other techniques for which all inputs which have a significant effect on the recorded fair value are observable, either directly or indirectly; and
- Level 3 : techniques which use inputs that have a significant effect on the recorded fair value that are not based on observable market data.

No financial assets or financial liabilities have been reclassified between the valuation categories during the period.

8. Changes in composition

During the course of the first six months of 2018, the structure of the Group did not change compared to the situation at the end of 2017.

9. Contingent consideration

The Company signed a sale and purchase agreement on September 18, 2015 to acquire all shares and voting interests of NovioGendix, an entity incorporated in The Netherlands.

Under the terms of the agreement, the Company is committed to pay up to $3.3 million subject to meeting certain milestones, be payable in six milestone payments.

The contingent consideration is valued at every reporting date and the change in fair value only relates to the time value of money, all other assumptions remained unchanged compared to December 31, 2017. This contingent liability has been evaluated to a fair-value of $1.5 million at the end of June 2018 and $ 409 thousand is included in the current liabilities and $ 1,101 thousand is included in non-current liabilities of the balance sheet.

10. Related party transactions

Transactions between MDxHealth SA, MDxHealth BV and MDxHealth Inc., which are related parties, have been eliminated on consolidation and are not disclosed in this note. The intercompany services between all the MDxHealth group entities relate to R&D and administrative services carried out by the subsidiary companies on behalf of the parent company and to administrative services carried out by the parent company for the subsidiaries.

Beside remuneration, warrants and bonus there are no other transactions to key personnel than these already mentioned in the 2017 financial statements. For the first half of 2018, the total remuneration for key management and Directors is $1.0 million, and they were granted a total of 70.000 warrants.

There were no other related party transactions.

11. Capital

On March 22, 2018, the Company raised EUR 36 million (USD 44,310 thousand) in gross proceeds by means of a private placement of 9,989,881 new shares at an issue price of EUR 3.60 per share through an accelerated bookbuilding. After deduction of the costs directly associated to the transaction, the net proceeds raised amounts to $42,423 thousand.

12. Warrant plans

The warrants were created within the context of stock based incentive plans for employees, directors and consultants of the Company.

The warrants are granted to employees (mainly), consultants or directors of the Company and its subsidiaries. Each warrant entitles its holders to subscribe to one new share of the Company at a subscription price determined by the board of directors, within the limits decided upon at the occasion of their issuance. The warrants issued have generally a term of ten years as of issuance. Upon expiration of their term, the warrants be-come null and void.

In general, the warrants vest in cumulative tranches of 25% per year, provided that the beneficiary has provided at least one year of service.

During the first half of 2018, the Company granted a total of 132.000 warrants to employees, consultants and directors of the Company and its subsidiaries. The warrants have been granted free of charge. Each warrant entitles its holders to subscribe to one common share of the Company at a subscription price determined by the board of directors, within the limits decided upon on issuance.

The fair value of each warrant was estimated on the date of grant using the Black-Scholes methodology with the following assumptions:

- The dividend return is estimated by reference to the historical dividend payment of the Group. Currently, this is estimated to be zero as no dividends have been paid since inception.
- The expected volatility was determined using the average volatility of the stock over the last two years at the date of grant.
- Risk-free interest rate is based on the interest rate applicable for the 10Y Belgian government bond at the grant date

The model inputs for warrants granted during the period ended June 30, 2018 included:

Grant date	April 1	May 1	June 1	June 1
Exercise price	€3.77	€3.64	€3.79	€4.97
Expiry date	3/31/2024	3/31/2024	3/31/2024	3/31/2027
Share price at grant date	€5.30	€5.29	€4.89	€4.89
Expected price volatility	46.08%	46.27%	46.15%	46.15%
Risk-free interest rate	0.76%	0.82%	0.77%	0.77%

The share based payment expense of the granted warrants was $544k for the first six months of 2018, following the underlying assumptions of the model.

13. Subsequent events

On July 23, 2018, MDxHealth announced that Palmetto GBA, a Medicare Administrative Contractor (MAC) that asesses molecular diagnostic technologies, has issued a positive final Local Coverage Determination (LCD) to expand Medicare coverage of the ConfirmMDx for Prostate Cancer test. The final LCD, which expands Medicare coverage to all providers, becomes effective on September 3, 2018. The prior LCD, first established in 2014, limited coverage to only those providers enrolled in a certification and training registry program (CTR). In addition, the new LCD removes other conditions to continuing Medicare coverage by deleting references to the Pascual clinical study, removing patient number limitations, and eliminating certain other conditions associated with the former MolDX coverage with data development (CDD) program.

On July 27, 2018, MDxHealth announced that a study validating the cost-effectiveness of SelectMDx® for Prostate Cancer, its non-invasive 'liquid biopsy' test that helps identify patients at increased risk of aggressive prostate cancer, has been published in The Journal of Urology. The study, designed to elucidate the cost-effectiveness of SelectMDx in a population of U.S. men with elevated PSA, modelled the impact of utilizing the non-invasive diagnostic test prior to ultrasound-guided prostate biopsy. The primary objective was to characterize changes in health outcomes, measured in quality-adjusted life years, and a secondary objective was evaluating healthcare costs from the Medicare payer perspective.

6. STATUTORY AUDITOR'S REPORT TO THE BOARD OF DIRECTORS OF MDXHEALTH SA ON THE REVIEW OF THE CONSOLIDATED INTERIM FINANCIAL INFORMATION FOR THE SIX-MONTH PERIOD ENDED JUNE 30, 2018

Introduction

We have reviewed the accompanying interim consolidated statement of financial position of MDxHealth SA as of June 30, 2018 and the related interim consolidated statements of comprehensive income, cash flows and changes in equity for the six-month period then ended, as well as the explanatory notes. The Board of Directors is responsible for the preparation and presentation of this consolidated interim financial information in accordance with IAS 34 "Interim Financial Reporting", as adopted by the European Union. Our responsibility is to express a conclusion on this consolidated interim financial information based on our review.

Scope of review

We conducted our review in accordance with International Standard on Review Engagements 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity". A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying consolidated interim financial information is not prepared, in all material respects, in accordance with IAS 34 "Interim Financial Reporting", as adopted by the European Union.

Zaventem, August 29, 2018

BDO Bedrijfsrevisoren Burg. Ven. CBVA / BDO Réviseurs d'Entreprises Soc. Civ. SCRL
Statutory auditor
Represented by Gert Claes

III. CORPORATE INFORMATION

Registered office

MDxHealth SA has the legal form of a public limited liability company (société anonyme - SA / naamloze vennootschap - NV) organized and existing under the laws of Belgium. The company's registered office is located at CAP Business Center, Rue d'Abhooz 31, B-4040 Herstal, Belgium.

The company is registered with the Registry of Legal Persons (registre des personnes morales - RPM / rechtspersonenregister – RPR) under company number RPM/RPR 0479.292.440 (Liège).

Listings
Euronext Brussels: MDXH

Financial calendar
October 23, 2018 – Second business update (Q3 2018)

Financial year
The financial year starts on 1 January and ends on 31 December.

Statutory auditor
BDO Bedrijfsrevisoren / Réviseurs d'entreprises CVBA/SCRL
Da Vincilaan 9
1935 Zaventem
Belgium

Availability of the Interim Report
This document is available to the public free of charge and upon request:
MDxHealth SA - Investor Relations
CAP Business Center - Rue d'Abhooz, 31 – 4040 Herstal - Belgium
Tel: +32 4 257 70 21
E-mail: ir@mdxhealth.com

For informational purposes, an electronic version of the Interim Report 2016 is available on the website of MDxHealth at www.mdxhealth.com/investors/financials